Prangthip Charoenpong, MD
Critical Care Medicine · Houston, TXNPI 1609130475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,737 and has fallen 69.2% since, to $535 in 2025.
Across 241 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$1K
- United Therapeutics Corporation$808
- GSK$651
- Boehringer Ingelheim$571
- AstraZeneca$432
- Merck$386
- plus $2K from 19 others
Across 34 payments — averaging $1786.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$61K
- GSK$206
What the payments were for
- Consulting fees$240%
- Food & beverage$5,78096%
- Education$1893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 59 | $1,289 |
| United Therapeutics Corporation | 16 | $808 |
| GSK | 28 | $651 |
| Boehringer Ingelheim | 29 | $571 |
| AstraZeneca(2 entities) | 14 | $432 |
| Merck | 26 | $386 |
| Insmed, Inc. | 14 | $239 |
| Johnson & Johnson | 12 | $197 |
| Astellas Pharma US Inc | 4 | $187 |
| Inari Medical, Inc. | 1 | $170 |
| Pfizer | 5 | $158 |
| Melinta Therapeutics, LLC | 3 | $147 |
| Baxter Healthcare | 4 | $140 |
| Vertex | 1 | $118 |
| Grifols USA, LLC | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Atricure, Inc. | 2 | $73 |
| E.r. Squibb & Sons, L.L.C. | 5 | $63 |
| AbbVie | 2 | $38 |
| Shionogi Inc | 2 | $34 |
| Gilead | 2 | $32 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Inogen, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$475
- UPTRAVI$475
- FLOWTRIEVER CATHETER, S$170
- CT THROMBECTOMY SYSTEM KIT$170
- LOKELMA$125
- FASENRA$125
- NUCALA$125
- TRIKAFTA$118
- TYVASO$112
How this compares
$5,993 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 41 | $506,893 |
| Orenitram ErTreprostinil Diolamine | 33 | $448,040 |
| OfevNintedanib Esylate | 22 | $309,670 |
| Azithromycin | 28 | $1,295 |
| Gabapentin | 12 | $338 |
| Fludrocortisone Acetate | 12 | $159 |
| Prednisone | 15 | $81 |
| Amlodipine Besylate | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,289 | $506,89341 claims |
| Boehringer IngelheimOfev | $571 | $309,67022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Houston
- Edwin ParsleyHouston$283K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Sami HossriHouston$34K
- George WilliamsHouston$33K
- Nicholas VillalobosHouston$26K
- Ranjan UpadhyayHouston$25K
- Deepa GoturHouston$23K
- Hany Abd-El MalekHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.